These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 6316304)
1. [Role of tissue microenvironment in immunity in the neoplastic process]. Janik P Pol Tyg Lek; 1983 May 30-Jun 6; 38(22-23):705-7. PubMed ID: 6316304 [No Abstract] [Full Text] [Related]
2. [Immunoreactivity in tumor growth]. Fel' VIa Vopr Onkol; 1987; 33(4):99-106. PubMed ID: 3296438 [No Abstract] [Full Text] [Related]
3. On immunosurveillance in human cancer. Thomas L Yale J Biol Med; 1982; 55(3-4):329-33. PubMed ID: 6758376 [TBL] [Abstract][Full Text] [Related]
4. Undercoat-constitutive proteins of cell-cell adherens junctions. Birchmeier W Jpn J Cancer Res; 1993 Aug; 84(8):inside front cover. PubMed ID: 8407542 [No Abstract] [Full Text] [Related]
5. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Allavena P; Sica A; Garlanda C; Mantovani A Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000 [TBL] [Abstract][Full Text] [Related]
6. [Breakdown of immunological surveillance]. Hosokawa M Nihon Rinsho; 1986 Feb; 44(2):305-10. PubMed ID: 3517409 [No Abstract] [Full Text] [Related]
7. [A new hypothesis on the immune surveillance of tumors]. Jansa P Acta Univ Palacki Olomuc Fac Med; 1984; 107():139-42. PubMed ID: 6242634 [No Abstract] [Full Text] [Related]
8. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Baglole CJ; Ray DM; Bernstein SH; Feldon SE; Smith TJ; Sime PJ; Phipps RP Immunol Invest; 2006; 35(3-4):297-325. PubMed ID: 16916756 [TBL] [Abstract][Full Text] [Related]
9. The immune response against dying tumor cells: avoid disaster, achieve cure. Zitvogel L; Kroemer G Cell Death Differ; 2008 Jan; 15(1):1-2. PubMed ID: 18084310 [No Abstract] [Full Text] [Related]
12. Escape from immune- and nonimmune-mediated tumor surveillance. Malmberg KJ; Ljunggren HG Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546 [TBL] [Abstract][Full Text] [Related]
13. Cycling in equilibrium or formed from noncycling cell transitions in tissue aging, immunological surveillance, transformation, and tumor growth. Gelfant S Int Rev Cytol; 1981; 70():1-25. PubMed ID: 7014503 [No Abstract] [Full Text] [Related]
14. [Cytotoxic cells of the NK type - their characteristics and role in anti-neoplastic immunity]. Janiak M; Lipski S Postepy Hig Med Dosw; 1982; 36(1-3):95-131. PubMed ID: 6763997 [No Abstract] [Full Text] [Related]
16. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Apte RN; Voronov E Immunol Rev; 2008 Apr; 222():222-41. PubMed ID: 18364005 [TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment and the immune response. Selleri S; Rumio C; Sabatino M; Marincola FM; Wang E Surg Oncol Clin N Am; 2007 Oct; 16(4):737-53, vii-viii. PubMed ID: 18022542 [TBL] [Abstract][Full Text] [Related]
18. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Gatenby RA; Gawlinski ET Cancer Res; 2003 Jul; 63(14):3847-54. PubMed ID: 12873971 [TBL] [Abstract][Full Text] [Related]
19. [Epithelial-mesenchymal transition in cancer progression]. Gos M; Miłoszewska J; Przybyszewska M Postepy Biochem; 2009; 55(2):121-8. PubMed ID: 19824467 [TBL] [Abstract][Full Text] [Related]
20. The evolving concept of tumor microenvironments. Laconi E Bioessays; 2007 Aug; 29(8):738-44. PubMed ID: 17621638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]